Table 2.
Multivariate Cox regression model results including age and continuous tumor volume (excluding necrosis) for newly diagnosed GBM patients treated with standard chemoradiation with and without experimental therapy
| Treatment | Dataset | Variable | Coefficient | Hazard Ratio | 95% CI | P-value |
|---|---|---|---|---|---|---|
| Chemoradiation | Discovery—UCLA (N = 398) | Age | 0.0243 ± 0.0047 | 1.0246 | (1.0153–1.0340) | <0.0001 |
| Volume | 0.0123 ± 0.0036 | 1.0124 | (1.0052–1.0196) | 0.0007 | ||
| Chemoradiation | Confirmation—Ivy Radiogenomics (N = 262) | Age | 0.0220 ± 0.0052 | 1.0222 | (1.0118–1.0327) | <0.0001 |
| Volume | 0.0199 ± 0.0069 | 1.0201 | (1.0064–1.0340) | 0.0038 | ||
| Chemoradiation | Validation—AVAglio PLC Arm (N = 394) | Age | 0.0264 ± 0.0060 | 1.0267 | (1.0147–1.0390) | <0.0001 |
| Volume | 0.0196 ± 0.0033 | 1.0198 | (1.0131–1.0264) | <0.0001 | ||
| Chemoradiation+Bevacizumab | AVAglio BV Arm (N = 404) | Age | 0.0132 ± 0.0053 | 1.0133 | (1.0029–1.0238) | 0.0122 |
| Volume | 0.0166 ± 0.0027 | 1.0167 | (1.0114–1.0221) | <0.0001 | ||
| Chemoradiation | Alliance N0874 (N = 53) | Age | 0.0181 ± 0.0150 | 1.0183 | (0.9888–1.03486) | 0.2271 |
| +Vorinostat | Volume | 0.0287 ± 0.0089 | 1.0291 | (1.0113–1.0473) | 0.0013 |
PLC = placebo. BV = bevacizumab.